In vitro effects of recombinant activated factor VIIa (NovoSeven) on clopidogrel-induced platelet inhibition

Thromb Haemost. 2010 Apr;103(4):863-5. doi: 10.1160/TH09-09-0632. Epub 2010 Feb 2.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine Diphosphate / blood
  • Aged
  • Aged, 80 and over
  • Angioplasty, Balloon, Coronary*
  • Clopidogrel
  • Coagulants / pharmacology*
  • Collagen / blood
  • Coronary Artery Disease / blood
  • Coronary Artery Disease / drug therapy
  • Coronary Artery Disease / therapy*
  • Factor VIIa / pharmacology*
  • Female
  • Hemorrhage / blood
  • Hemorrhage / chemically induced
  • Hemorrhage / prevention & control
  • Humans
  • Male
  • Middle Aged
  • Platelet Aggregation / drug effects*
  • Platelet Aggregation Inhibitors / adverse effects
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Recombinant Proteins / pharmacology
  • Thrombin / metabolism
  • Ticlopidine / adverse effects
  • Ticlopidine / analogs & derivatives*
  • Ticlopidine / therapeutic use
  • Time Factors
  • Treatment Outcome

Substances

  • Coagulants
  • Platelet Aggregation Inhibitors
  • Recombinant Proteins
  • Adenosine Diphosphate
  • Collagen
  • Clopidogrel
  • recombinant FVIIa
  • Factor VIIa
  • Thrombin
  • Ticlopidine